OverviewSuggest Edit

Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

HQMumbai, IN
Employee Ratings3.8

Latest Updates

Employees (est.) (Sept 2020)18,302(+4%)
Share Price (Sept 2020)₹968
Cybersecurity ratingFMore

Key People/Management at Lupin

Manju D Gupta

Manju D Gupta

Kamal K Sharma

Kamal K Sharma

Vice Chairman
Vinita Gupta

Vinita Gupta

Chief Executive Officer, Director
Nilesh Deshbandhu Gupta

Nilesh Deshbandhu Gupta

Managing Director
Richard Zahn

Richard Zahn

Independent Director
K U Mada

K U Mada

Independent Director
Show more

Lupin Office Locations

Lupin has offices in Mumbai, Baltimore and Zug
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Mumbai, IN
3rd Floor, Kalpataru Inspire Off. Western Expressway, Highway, Shanti Nagar, Vakola, Santacruz East
Zug, CH
1 Landis + Gyr-Strasse
Baltimore, US
111 S Calvert St 21st floor
Show all (4)

Lupin Financials and Metrics

Lupin Revenue

Market capitalization (14-Sept-2020)


Closing stock price (14-Sept-2020)

Lupin's current market capitalization is ₹451.3 b.
Show all financial metrics

Lupin Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Lupin Online and Social Media Presence

Embed Graph

Lupin News and Updates

Lupin Gets Long-Pending U.S. FDA Approval For Key Generic Asthma Drug

ProAir generic will be manufactured at Lupin’s Indore (unit III) facility in India.

Lupin, Sun Pharma Recall Drugs In The U.S. Market

Lupin is recalling 11,688 bottles of Lisinopril tablets while Sun Pharma is recalling 3,516 bottlews of Clonazepam.

Live: SGX Nifty Indicates A Flat Start; Cipla, Pidilite, M&M, Lupin In Focus

Catch all live updates on share prices, index moves, corporate announcements and more from the Sensex and Nifty, today.

Lupin Launches Covid-19 Drug Favipiravir In India At Rs 49 Per Tablet

Lupin to launch Favipiravir drug in India under the brand name ‘Covihalt’ for the treatment of mild to moderate Covid-19 symptoms.

Global Lupin Seed Market to Witness a Pronounce Growth During 2025

According to this study, over the next five years the Lupin Seed market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Lupin Seed…

Lupin, Granules India Recall Around 9.71 Lakh Bottles Of Diabetes Drug In U.S.

The affected lot is suspected of having cancer-causing nitrosodimethylamine above the acceptable intake limit.
Show more

Lupin Frequently Asked Questions

  • When was Lupin founded?

    Lupin was founded in 1968.

  • Who are Lupin key executives?

    Lupin's key executives are Manju D Gupta, Kamal K Sharma and Vinita Gupta.

  • How many employees does Lupin have?

    Lupin has 18,302 employees.

  • Who are Lupin competitors?

    Competitors of Lupin include Mito BioPharma, Patagonia Pharmaceuticals and Sciwind.

  • Where is Lupin headquarters?

    Lupin headquarters is located at Laxmi Towers BKC Road, Mumbai.

  • Where are Lupin offices?

    Lupin has offices in Mumbai, Baltimore and Zug.

  • How many offices does Lupin have?

    Lupin has 4 offices.